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SObjective: Radiofrequency ablation can eradicate Barrett’s esophagus successfully in the majority of cases. We
sought to determine (1) how often intestinal metaplasia is detected during follow-up endoscopy after successful
ablation and (2) patterns of persistent/recurrent intestinal metaplasia.
Methods: Patients ablated successfully during a phase II clinical trial of radiofrequency ablation for Barrett’s
esophagus were followed using endoscopic surveillance according to a defined protocol. Systematic biopsies
were performed in all patients throughout the neosquamous epithelium as well as at the gastroesophageal junc-
tion, and patterns of recurrent or persistent intestinal metaplasia were documented.
Results: Fifty-three patients were ablated successfully during this single-institution clinical trial. A total of 151
follow-up endoscopies were performed (range, 1-5 endoscopies per patient) and 2492 biopsies were obtained, of
which 604 (24%) were from the gastroesophageal junction. The median follow-up period was 18months (range,
3-50 months). Recurrent/persistent intestinal metaplasia was detected in 14 patients (26%) in 3 distinct patterns:
endoscopically invisible intestinal metaplasia underneath the neosquamous epithelium (buried glands) in 3 pa-
tients, visible recurrence in the tubular esophagus in 3 patients, and intestinal metaplasia of the gastroesophageal
junction (with a squamous-lined tubular esophagus) in 10 patients. Dysplasia or cancer was not detected in any
patient during the follow-up period.
Conclusions: Recurrent/persistent intestinal metaplasia after successful radiofrequency ablation of Barrett’s
esophagus is relatively common. This finding has implications for the continued surveillance of patients who
are ablated successfully. (J Thorac Cardiovasc Surg 2013;145:1529-34)Earn CME credits at
http://cme.ctsnetjournals.org
Radiofrequency ablation (RFA) is established as an effec-
tive procedure for the eradication of Barrett’s esophagus
(BE).1,2 Success rates using this technology have
been reported to range from 40% to 100% for the
elimination of intestinal metaplasia (IM) from the tubular
esophagus.1-11 Furthermore, complication rates are low,
and a recent, randomized clinical trial has demonstrated
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Despite these advantages, the majority of patients require
multiple treatment sessions, especially those with long
columnar segments and large hiatal hernias.12
After successful ablation of BE, it becomes potentially
important to determine whether IM persists in some fashion
or recurs, because IM is thought to be the premalignant
lesion in BE.13 Histologic assessment of the post-RFA
esophagus is performed by surveillance endoscopy with
systematic biopsies of the neosquamous epithelium. Al-
though IM after ablation has been reported to occur in the
form of buried glands (representing persistent IM)—in
which glandular mucosa underlies stratified squamous
epithelium, giving the endoscopic appearance of a grossly
normal esophagus14—the phenomenon of actual recurrence
of BE is not well described. In addition, a paucity of
published data exist regarding the histologic state of the
gastroesophageal junction after RFA in the tubular
esophagus, with a single retrospective study addressing
this issue specifically.15 Given the lack of information re-
garding persistent IM, recurrent IM, and the histologic
state of the gastroesophageal junction after RFA, the
current study characterizes these phenomena using
follow-up from a prospective clinical trial that evaluated
RFA for BE.diovascular Surgery c Volume 145, Number 6 1529
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
IM ¼ intestinal metaplasia
PPI ¼ proton pump inhibitor
RFA ¼ radiofrequency ablation
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Clinical Trial
A phase II clinical trial of RFA for BE was performed between 2007
and 2011 at a single institution after approval by the institutional review
board. All patients signed informed consent. Barrett’s esophagus was de-
fined as an esophageal columnar segment>3 cm in length regardless of
whether IM was detected by biopsy or an esophageal columnar segment
<3 cm with biopsy-proved IM. Patients with IM of the gastroesophageal
junction without a columnar-lined esophagus were not included in this
trial. The initial success rates of eradicating BE were published previ-
ously, along with the clinical trial details.12 Success was defined as
establishment of squamous epithelium (confirmed histologically)
throughout the tubular esophagus as visualized using both white light
and narrow-band imaging. Two months after the last ablation, all patients
underwent a single follow-up endoscopy, during which the success of the
procedure was established. This initial follow-up endoscopy was not
considered part of the follow-up protocol. As part of the clinical trial,
all successfully ablated patients underwent scheduled endoscopic
follow-up according to a rigorous protocol depending on patients’ prea-
blation histologic diagnosis, as shown in Table 1. During each endos-
copy, inspection of the mucosa was performed using white light and
narrow-band imaging, and systematic biopsies were performed. Success-
fully ablated patients who had IM discovered at the gastroesophageal
junction (cardia) at follow-up endoscopy did not undergo further abla-
tion because they did not meet the definition of BE established when
the protocol was written.
After successful RFA, a proton pump inhibitor (PPI) dose was main-
tained at a level that provided relief from gastroesophageal reflux symp-
toms. The performance of hiatal hernia repair and fundoplication was
left up to the discretion of the principal investigator (R.J.K.), but was
mainly symptom directed.
Biopsy Protocol
At each endoscopic examination, a systematic biopsy protocol was fol-
lowed in all patients, which included 4 quadrant biopsies, performed at 1 to
2-cm intervals throughout the entire segment of neosquamous epithelium
using jumbo biopsy forceps (Radial jaw 4; Boston Scientific, Natick,
Mass). In addition, 4 quadrant biopsies were performed routinely just infe-
rior to the ‘‘new’’ squamocolumnar junction (the gastroesophageal junc-
tion). If, at the time of endoscopic examination, a significant region of
mucosal irregularity was identified in a columnar-lined area, it was re-
moved using endoscopic mucosal resection. Biopsy specimens were fixed
in formalin, embedded in paraffin, cut, and stained with hematoxylin and
eosin.
Data Collection
Data collected for the current analysis included patient demographics,
length of BE, size of hiatal hernia, number of post-RFA endoscopies, num-
ber of post-RFA biopsies, length of follow-up after the last ablation, recur-
rence of BE, the presence of buried glands, and the presence of IM with or
without dysplasia of the gastroesophageal junction. Recurrent BE was de-
fined as the recurrence of a grossly visible columnar lining within the tubu-
lar esophagus, with histologic confirmation of IM. Buried glands were1530 The Journal of Thoracic and Cardiovascular Surdefined as glandular epithelium present underneath stratified squamous
epithelium.
Statistical Analysis
Follow-up data were analyzed using the Kaplan-Meier methodology,
and the probability of being recurrence free was plotted. IBM-SPSS Statis-
tics software (version 19;Armonk, NY)was used for the statistical analysis.RESULTS
Patient Characteristics
Fifty-three patients were treated successfully using RFA
for BE on this phase II protocol. There were 37 males and
16 females, with a median age of 59 years (age range,
24-85 years). The median length of the initial columnar seg-
ment was 3 cm (range, 1-16 cm) and the median hiatal her-
nia size was 2 cm (range, 0-8 cm). Forty patients (75%) had
nondysplastic BE, whereas 4 patients (8%) had low-grade
dysplasia, 4 (8%) had high-grade dysplasia, and 4 (8%)
were read as indefinite for dysplasia. One patient had
a T1a adenocarcinoma removed using endoscopic mucosal
resection prior to RFA for the remaining BE. All patients
had IM present in their columnar segments prior to ablation.
Endoscopic Follow-up
A total of 151 follow-up endoscopies were performed on
this cohort of 53 patients (median, 3 per patient; range, 1-5
per patient) and a total of 2492 biopsies were evaluated his-
tologically (median, 36 per patient; range, 8-156 per pa-
tient). Biopsies obtained from the gastroesophageal
junction totaled 604 (24% of total biopsies). The median
follow-up period was 18 months (range, 3-50 months).
Figure 1 demonstrates follow-up compliance for the 51 pa-
tients who entered the follow-up protocol. Two patients
have been ablated successfully but have not yet undergone
their first endoscopy in the follow-up protocol. Recurrent
and/or persistent IM was detected at some point during
the follow-up period in 14 of 53 successfully ablated pa-
tients (26%). Figure 2 demonstrates the probability of being
recurrence free based on the follow-up data.Buried Glands
Buried glands were detected at some point after success-
ful ablation in 3 biopsies from 3 patients (6% of patients,
0.2% of biopsies from the tubular esophagus). All 3 patients
had at least 3 post-RFA endoscopies, and in no patient was
dysplasia detected. The clinical characteristics of these 3
patients are displayed in Table 2.Recurrence of Barrett’s Esophagus
Recurrent BE was detected endoscopically and confirmed
histologically in 3 patients (6%). In all 3 instances, new
tongues of columnar lining (1-2 cm in length)werevisualized
in the presence of active esophagitis, and biopsies confirmed
IM, without dysplasia. After their successful initial ablation,gery c June 2013
TABLE 1. Follow-up protocol after successful ablation
Preablation histologic diagnosis Endoscopy interval
BE, but no dysplasia Every 6 months for 1 year, then
every year for 2 years, then every
2 years
BE with either low-grade dysplasia,
or indeterminate for dysplasia
Every 6 months for 2 years, then
every year for 2 years, then every
2 years
High-grade dysplasia or T1a
carcinoma
Every 3 months for 1 year, then
every 6 months for 3 years, then
every year
BE, Barrett’s esophagus.
Korst et al General Thoracic Surgeryall 3 patients had lowered their PPI dose to the dose theywere
taking prior to ablation. The clinical characteristics of these
3 patients are shown in Table 3.FIGURE 2. Kaplan-Meier analysis demonstrating the cumulative proba-
bility of being recurrence free from intestinal metaplasia after successful
radiofrequency ablation of Barrett’s esophagus. G
T
SIntestinal Metaplasia of the Gastroesophageal
Junction
After successful ablation, 10 patients (19%) were diag-
nosed with IM of the gastroesophageal junction, despite
having a squamous-lined tubular esophagus. Dysplasia
was not detected in any patient. Table 4 presents the clinical
characteristics and persistence of IM of the gastroesopha-
geal junction in these 10 patients. Nine of these patients
were ablated initially for nondysplastic BE, with the 10th
patient having high-grade dysplasia prior to ablation.Postablation Gastroesophageal Reflux Control
After successful ablation, 15 patients (28%) decreased
their PPI dose down to the level they were taking prior to
ablation. Thirty-four patients (64%) were maintained on
the elevated PPI dose used for ablation. Four patients
(8%) underwent hiatal hernia repair and fundoplication.FIGURE 1. Adherence to the follow-up protocol for 51 successfully
ablated patients. Two recently successfully ablated patients have not yet
entered the follow-up protocol.
The Journal of Thoracic and CarTwo were performed after successful ablation, 1 was per-
formed prior to any ablation attempts, and the 4th was per-
formed after an initial attempt at ablation failed to heal with
squamous mucosa. This last patient then underwent suc-
cessful ablation after his fundoplication. These 4 patients
eliminated their regular PPI use after successful ablation.
The patient who underwent hernial repair prior to ablation
had recurrence of IM in the form of buried glands as well
as IM of the gastroesophageal junction (Tables 2 and 4,
patient no. 006).
DISCUSSION
Barrett’s esophagus is a premalignant condition of the
esophagus caused by chronic gastroesophageal reflux. The
risk of developing adenocarcinoma of the esophagus in the
setting of BE is not clear, but estimates have ranged from
0.1% to 0.5% per patient, per year of follow-up, with the
risk being cumulative over time.16 As a result, ablative
techniques have been developed aimed at eliminating the
columnar lining and replacing it with stratified squamous
epithelium. We have published previously our initial results
with eradication of BE using RFA from a phase II clinical
trial at our institution conducted between 2007 and 2011,
with an intent-to-treat success rate of 78% (91% ‘‘per pro-
tocol’’ success rate).12 The current analysis addresses the
follow-up of the successfully ablated patients from this clin-
ical trial, focusing on the persistence and recurrence of IM.
Intestinal Metaplasia in the Postablation Tubular
Esophagus
In the current study, IM of the tubular esophagus detected
during the follow-up period took 2 forms: buried glandsdiovascular Surgery c Volume 145, Number 6 1531
TABLE 2. Clinical features of patients with buried glands found after successful ablation
Patient no.
Preablation
histology
Initial BE
length, cm
Level of buried
glands, cm*
Level of ‘‘new’’
squamocolumnar
junction, cm*
Timing of positive endoscopyy
1st 2nd 3rd 4th 5th
007 HGD 10 36 40 N N N N Y
006 Nondysplastic 16 38 42 N Y N NP N
017 Nondysplastic 5 26 30 Y N N — —
BE, Barrett’s esophagus; HGD, high-grade dysplasia; N, buried glands not detected; Y, buried glands detected; NP, endoscopy at designated time interval was not performed; —,
follow-up time point has not yet been reached. *Distance from incisors. yPostablation endoscopies were performed according to the schedule in Table 1.
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current tongues of endoscopically visible columnar lining.
Buried glands have been reported in patients with BE
both before and after attempts at ablation, regardless of
the ablative technique used.14,17 In the presence of BE,
buried glands are usually associated with squamous
islands located within the columnar segment.17 Indeed, in
the randomized trial of RFA for dysplastic BE, Shaheen
and colleagues1 found buried glands in 25.2% of patients
prior to treatment randomization. In contrast, buried glands
were not detected in any patient from the current study prior
to ablation, perhaps because the protocol did not mandate
routine sampling of the squamous mucosa prior to ablation.
Buried glands after RFA are uncommon, and have been
found in less than 10% of patients enrolled in clinical
trials evaluating RFA.1-11 Results from the clinical trial
reported herein corroborate this finding, with only 6%
of successfully ablated patients demonstrating this
phenomenon at some point during their follow-up. Interest-
ingly, all biopsies showing buried glands were located a sub-
stantial distance away from any visible columnar mucosa
(Table 2). Although buried glandular tissue has been re-
ported to harbor dysplasia and even malignancy,14 this
was not the case in the current study.
Visible recurrence of BE in the tubular esophagus after
successful RFA has been described only vaguely. Existing
reports describe recurrences in the region of the gastro-
esophageal junction, making it difficult to discern whether
these cases represent actual recurrence in the esophagus
or simply IM of the gastroesophageal junction in the pres-
ence of a visibly normal tubular esophagus.1,2 In the
current study, 3 clear-cut recurrences were detected, in
which new tongues of columnar lining were identified in
the tubular esophagus. All cases occurred in patients who
had lowered their PPI dose back down to their preablationTABLE 3. Clinical features of patients with recurrent Barrett’s esophagus
Patient no. Preablation histology Initial BE length, cm Size of h
023 Nondysplastic 4
053 Nondysplastic 2
028 Nondysplastic 5
BE, Barrett’s esophagus; N, recurrence not detected; NP, endoscopy at designated time int
been reached. *Distance between the top of the gastric folds and the crural pinch. yPostab
1532 The Journal of Thoracic and Cardiovascular Surdose (which had been doubled for the duration of the abla-
tion sessions). In addition, all 3 cases were associated with
the presence of endoscopically visible esophagitis. Whether
successfully ablated patients should be maintained at
a higher PPI dose after RFA remains to be determined,
but this represents a relevant question based on these results.
Intestinal Metaplasia of the Gastroesophageal
Junction
The most common circumstance in which IM was de-
tected after successful RFA of the tubular esophagus in
the current trial was immediately inferior to the ‘‘new’’
squamocolumnar junction (cardia of stomach). Because
the protocol mandated the routine that 4 quadrant biopsies
be acquired in this region using jumbo forceps, every pa-
tient’s gastroesophageal junction was evaluated during
every postablation endoscopic examination. There is a pau-
city of prospective, published data addressing this phenom-
enon because routine sampling of this area was not
performed in several of the clinical trials evaluating RFA
for BE.1,2,6 In the prospective trials in which it was
evaluated, IM of the gastroesophageal junction was not as
frequent as described herein (19% of successfully
ablated patients), ranging from 0% to 18% of patients.3-5
The 19% frequency described in the current study,
however, supports the retrospective analysis performed by
Vaccaro and colleagues,15 in which IM of the gastroesoph-
ageal junction was detected in 11 of 49 successfully ablated
patients (22%).
The significance of IM of the gastroesophageal junction
detected in patients in whom the tubular esophagus has
been ablated successfully using RFA is unknown. It is un-
clear whether these patients developed recurrent IM in
this area or whether this finding represents persistent IM,
because the cardia was not ablated in this trial. Intestinalwith intestinal metaplasia
iatal hernia, cm*
Timing of positive endoscopyy
1st 2nd 3rd 4th 5th
4 N N NP Y —
5 N NP Y N —
8 Y N N — —
erval was not performed; Y, recurrence detected; —, follow-up time point has not yet
lation endoscopies were performed according to the schedule in Table 1.
gery c June 2013
TABLE 4. Clinical features of patients with intestinal metaplasia of the gastroesophageal junction detected after successful radiofrequency
ablation
Patient no. Preablation histology Initial BE length, cm Size of hiatal hernia, cm*
Timing of positive endoscopyy
1st 2nd 3rd 4th 5th
009 Nondysplastic 1 0 N Y N N —
036 Nondysplastic 1 2 N N Y Y —
042 Nondysplastic 6 4 Y N N — —
024 Nondysplastic 2 0 N Y Y N N
059 Nondysplastic 2 3 Y N N Y —
069 Nondysplastic 3 3 Y N N — —
007 HGD 10 2 N N Y N N
081 Nondysplastic 3 0 Y N Y — —
094 Nondysplastic 2 2 Y N — —
006 Nondysplastic 16 2 Y Y Y NP Y
BE, Barrett’s esophagus; N, intestinal metaplasia of the gastroesophageal junction is not detected; Y, intestinal metaplasia of the gastroesophageal junction is detected; —,
follow-up time point has not yet been reached;HGD, high-grade dysplasia;NP, endoscopy at designated time interval was not performed. *Distance between the top of the gastric
folds and the crural pinch. yPostablation endoscopies were performed according to the schedule in Table 1.
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Smetaplasia of the gastroesophageal junction is a common
finding in patients without BE who undergo upper endos-
copy for nonreflux-related reasons.18 Although the malig-
nant potential of this finding in such patients is unclear,
causally it seems to be related to chronic inflammation.
Whether this inflammation is a result of gastroesophageal
reflux, Helicobacter pylori infection, or other factors re-
mains controversial.19 A potential shortcoming of this clin-
ical trial is that patients did not have routine, preablation
biopsies of the distal stomach evaluating for H pylori infec-
tion, although given the advanced state of their gastroesoph-
ageal reflux, it seems unlikely that Helicobacter-induced
IM of the stomach would have been a significant contribu-
tor. The significance of IM of the gastroesophageal junction
detected in the postablation setting is completely unknown
and may represent a completely different lesion than that
found de novo in the absence of BE. Given the absence of
data, the proper course of action is unclear. Options include
continued RFA of the gastroesophageal junction and cardia,
continued surveillance with systematic biopsies, or no fur-
ther treatment/surveillance.
Ablation of Nondysplastic Barrett’s Esophagus
The current study was conducted in the context of a phase
II clinical trial, with the majority of patients having nondys-
plastic BE. It is currently controversial whether nondysplas-
tic patients should be offered RFA outside a clinical trial
setting. Because of the low risk of nondysplastic patients
(as a group) progressing to adenocarcinoma, it has been ar-
gued that RFA represents overtreatment for these patients.20
The counterargument, however, states that RFA for nondys-
plastic patients should be individualized, because the malig-
nant risk may not be the same for all nondysplastic
segments, because RFA is such a safe technology, and be-
cause the alternative of surveillance endoscopy with biop-
sies has proven shortcomings.21 Until further prognostic
information is obtained, this issuewill remain controversial.The Journal of Thoracic and CarCONCLUSIONS
The detection of IM after successful RFA of BE is com-
mon, occurring in 26% of individuals treated with this tech-
nology. Although the incidence of buried glands and
endoscopically visible recurrence of IM is uncommon, the
presence of IM of the gastroesophageal junction is encoun-
tered more frequently—the significance of which is un-
known—but has implications for further surveillance after
successful RFA.
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